Indegene (BOM:544172) EPS (Basic) : ₹11.77 (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Indegene EPS (Basic)?

Indegene's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was ₹3.84. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹11.77.

Indegene's EPS (Diluted) for the three months ended in Sep. 2024 was ₹3.80. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹11.70.

Indegene's EPS without NRI for the three months ended in Sep. 2024 was ₹3.80. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was 11.36.

During the past 12 months, Indegene's average EPS without NRIGrowth Rate was 199.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Indegene EPS (Basic) Historical Data

The historical data trend for Indegene's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indegene EPS (Basic) Chart

Indegene Annual Data

Trend

Mar21

Mar22

Mar23

EPS (Basic)

6.24

6.89

11.12

Indegene Quarterly Data
	Mar21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial				2.86	3.14	4.14	3.79	3.84

Indegene EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Indegene's Basic EPS for the fiscal year that ended in Mar. 2023 is calculated as

Basic EPS (A: Mar. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(2660.99	-	0)	/	239.269
	=	11.12

Indegene's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(917	-	0)	/	238.802
	=	3.84

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11.77

Indegene (BOM:544172) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Indegene EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Indegene's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Indegene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Indegene Ltd (BOM:544172) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

INDGN:India

Address

Outer Ring Road, Aspen Block G4, 3rd Floor, Manyata Embassy Business Park, Nagawara, Bengaluru, KA, IND, 560045

Website

https://www.indegene.com

Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies. The company segment includes Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment.

Indegene Headlines

No Headlines